Enliven Therapeutics, Inc. (ELVN)
NASDAQ·Healthcare·Biotechnology
$42.91
-4.43%
Mkt Cap $2.74B
EPS — Estimate vs Actual
Revenue — Estimate vs Actual
Quarterly History
| Q1 2026 Mar 3, 2026 | $12.50K | — | — | -$0.42 | -$0.48 | -14.29% | — | — |
| Q4 2025 Nov 12, 2025 | $8.33K | — | — | -$0.43 | -$0.32 | +25.58% | — | — |
| Q3 2025 Aug 13, 2025 | — | — | — | -$0.53 | -$0.49 | +7.55% | — | — |
| Q2 2025 May 14, 2025 | — | — | — | -$0.51 | -$0.57 | -11.76% | — | — |
| Q1 2025 Mar 13, 2025 | — | — | — | -$0.53 | -$0.46 | +13.21% | — | — |
| Q4 2024 Nov 13, 2024 | — | — | — | -$0.52 | -$0.48 | +7.69% | — | — |
| Q3 2024 Aug 13, 2024 | — | — | — | -$0.58 | -$0.41 | +29.31% | — | — |
| Q2 2024 May 14, 2024 | — | — | — | -$0.58 | -$0.54 | +6.90% | — | — |
| Q1 2024 Mar 14, 2024 | — | $440.00K | — | -$0.56 | -$0.47 | +16.07% | — | — |
| Q4 2023 Nov 9, 2023 | — | — | — | -$0.49 | -$0.51 | -4.08% | — | — |
| Q3 2023 Aug 10, 2023 | — | — | — | -$0.40 | -$0.41 | -2.50% | — | — |
| Q2 2023 May 11, 2023 | — | — | — | -$0.67 | -$0.80 | -19.40% | — | — |
| Q1 2023 Feb 10, 2023 | — | — | — | -$0.79 | $1.23 | +256.49% | — | — |
| Q4 2022 Oct 25, 2022 | — | — | — | -$1.00 | -$0.72 | +28.00% | — | — |
| Q3 2022 Aug 3, 2022 | — | — | — | -$2.05 | -$1.76 | +14.15% | — | — |
| Q2 2022 May 6, 2022 | — | — | — | -$2.31 | -$2.24 | +3.03% | — | — |
| Q1 2022 Mar 15, 2022 | — | — | — | -$3.00 | -$2.12 | +29.33% | — | — |
| Q4 2021 Nov 9, 2021 | — | — | — | -$3.38 | -$2.20 | +34.91% | — | — |
| Q3 2021 Aug 6, 2021 | — | — | — | -$3.20 | -$2.96 | +7.50% | — | — |
| Q2 2021 May 11, 2021 | — | — | — | -$3.34 | -$2.32 | +30.54% | — | — |